Health
4.8
Ireland HSE assessment recommends Wegovy for select patients despite cost
Published 1 d ago1 sourceEvidence: Reported
SeverityModerateRTÉLow-rated sourceIE
An Irish health technology review suggests the HSE could reimburse Wegovy for certain patient groups, but estimates the cost in the billions. The decision is pending and hinges on budget allocation and clinical criteria. This signals a potential major expansion of public access to weight-loss drugs in Ireland.
Published 1 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Unknown
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago3 sourcesEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported